Sanofi and GlaxoSmithKline (GSK) have signed a letter of intent for a partnership focused on developing an adjuvanted vaccine for Covid-19.
While Sanofi and GSK are also working separately to enable vaccines for the viral infection, the latest alliance is intended to combine their respective technologies.
As part of the collaboration, Sanofi will provide its S-protein Covid-19 antigen based on recombinant DNA technology, used to generate an ‘exact genetic match’ to proteins present on the SARS-CoV-2’s surface.
Furthermore, Sanofi combined the DNA sequence encoding the antigen with the DNA of the baculovirus expression platform, which supported the company’s licensed recombinant influenza product in the US.